MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer

Acquired resistance is inevitable in non–small cell lung cancers (NSCLCs) treated with osimertinib (OSI), and the mechanisms are not well defined. The MERTK ligand GAS6 promoted downstream oncogenic signaling in EGFR-mutated (EGFRMT) NSCLC cells treated with OSI, suggesting a role for MERTK activati...

Full description

Bibliographic Details
Published in:	The Journal of Clinical Investigation
Main Authors:	Dan Yan, Justus M. Huelse, Dmitri Kireev, Zikang Tan, Luxiao Chen, Subir Goyal, Xiaodong Wang, Stephen V. Frye, Madhusmita Behera, Frank Schneider, Suresh S. Ramalingam, Taofeek Owonikoko, H. Shelton Earp, Deborah DeRyckere, Douglas K. Graham
Format:	Article
Language:	English
Published:	American Society for Clinical Investigation 2022-08-01
Subjects:	Cell biology Oncology
Online Access:	https://doi.org/10.1172/JCI150517

Similar Items

Beyond growth signaling: apoptotic sensor MERTK activates AKT by a novel mechanism
by: Yanqiong Zhang, et al.
Published: (2019-07-01)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
by: Igor Makhlin, et al.
Published: (2019-11-01)

Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLC
by: Y. Uehara, et al.
Published: (2024-09-01)

iMer, a naturally occurring MERTK splice variant, binds to GAS6 to decrease platelet activation and thrombus formation
by: Stephanie Springborn, et al.
Published: (2025-08-01)

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib
by: Vincent D. de Jager, et al.
Published: (2024-05-01)

Osimertinib-induced aplastic anemia after curative surgery for EGFR-mutant lung adenocarcinoma
by: Tomoyuki Kawamura, et al.
Published: (2025-01-01)

Successful Treatment of Osimertinib Resistance in an EGFR‐Mutant Lung Cancer Patient With a Rare STRN3‐ALK Fusion Using Brigatinib and Osimertinib
by: Chia‐Yu Kuo, et al.
Published: (2025-07-01)

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance
by: Jiao‐Li Wang, et al.
Published: (2022-11-01)

DNA topoisomerase II inhibition potentiates osimertinib’s therapeutic efficacy in EGFR-mutant non–small cell lung cancer models
by: Zhen Chen, et al.
Published: (2024-05-01)

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
by: Soei Gen, et al.
Published: (2022-06-01)

Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
by: Marcin Skrzypski, et al.
Published: (2017-09-01)

First-line Osimertinib for Lung Cancer With Uncommon EGFR Exon 19 Mutations and EGFR Compound Mutations
by: Tia Cheunkarndee, BA, et al.
Published: (2024-06-01)

A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib
by: Arturo Simoni-Nieves, et al.
Published: (2024-09-01)

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience
by: A.J. Piper-Vallillo, MD, et al.
Published: (2022-06-01)

Clinicopathological impact of VEGFR2 and VEGF‐C in patients with EGFR‐major mutant NSCLC receiving osimertinib
by: Kyoichi Kaira, et al.
Published: (2023-10-01)

Comparison of osimertinib plus bevacizumab against osimertinib alone in NSCLC harboring EGFR mutations: a systematic review and meta-analysis
by: Guojin Zhou, et al.
Published: (2024-01-01)

Osimertinib plus chemotherapy versus osimertinib for patients with advanced NSCLC with concomitant EGFR and TP53 mutations: a prospective cohort study
by: Jixian Li, et al.
Published: (2025-07-01)

Advanced EGFR-mutant NCSLC resistant to osimertinib therapy as a result of a novel CGN-RET fusion mutation with favorable response to combined osimertinib and selpercaptinib, case report
by: Hamid Mirshahidi, et al.
Published: (2023-09-01)

ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC
by: Caterina De Rosa, et al.
Published: (2024-01-01)

Osimertinib: A Game-Changer in Stage IV EGFR-Driven Lung Cancer
by: Sofia Silva, et al.
Published: (2025-04-01)

The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells
by: Steven W. Criscione, et al.
Published: (2022-12-01)

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study
by: Jingran Ji, MD, et al.
Published: (2023-03-01)

MERTK Inhibition: Potential as a Treatment Strategy in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer
by: Chao-Ju Chen, et al.
Published: (2021-02-01)

Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
by: Hsu-Yuan Chen, et al.
Published: (2024-10-01)

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
by: Ken Uchibori, et al.
Published: (2017-03-01)

Regulation of bone homeostasis by MERTK and TYRO3
by: Janik Engelmann, et al.
Published: (2022-12-01)

PD-L1 regulates c-MET phosphorylation and contributes to MET-dependent resistance to osimertinib in EGFR-mutant NSCLC
by: Chia-Chi Hsu, et al.
Published: (2025-10-01)

Phosphoproteomic Analysis Identified Mutual Phosphorylation of FAK and Src as a Mechanism of Osimertinib Resistance in EGFR-Mutant Lung Cancer
by: Takehiro Tozuka, MD, et al.
Published: (2024-04-01)

Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
by: Ou Yamaguchi, et al.
Published: (2023-11-01)

Intracranial Outcomes of De Novo Brain Metastases Treated With Osimertinib Alone in Patients With Newly Diagnosed EGFR-Mutant NSCLC
by: Brandon S. Imber, MD, MA, et al.
Published: (2023-12-01)

Correction: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer
by: Yali Yi, et al.
Published: (2022-06-01)

Targeting the EMT transcription factor Snail overcomes resistance to osimertinib in EGFR‐mutant non‐small cell lung cancer
by: Qiong Qin, et al.
Published: (2021-06-01)

Protocol for a systematic review with prospective individual patient data meta-analysis in EGFR-mutant NSCLC with brain metastases to assess the effect of SRS+osimertinib compared to osimertinib alone: the STARLET Collaboration
by: Ross Andrew Soo, et al.
Published: (2024-07-01)

Osimertinib retreatment for patients with advanced EGFR-mutated non-small cell lung cancer
by: Kevin M. Levine, et al.
Published: (2025-01-01)

Combination of Lurbinectedin and Osimertinib for Treatment of EGFR-Mutated Transformed SCLC: A Brief Report
by: Aditi Singh, MBBS, MPH, et al.
Published: (2025-06-01)

Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M
by: Xiaoying Zhang
Published: (2021-06-01)

Adenocarcinoma Harboring EGFR-RAD51 Fusion Treated With Osimertinib: A Case Report
by: Sunny Y. Lai, MD, et al.
Published: (2024-04-01)

Treatment Patterns and Resource Use After Osimertinib Discontinuation in Patients with EGFR + Metastatic NSCLC
by: Elizabeth Marrett, et al.
Published: (2024-07-01)

Prolonged Response to Osimertinib in EGFR-Mutated Metastatic Urothelial Carcinoma, a Case Report
by: Sareen T. Ali, et al.
Published: (2024-07-01)

Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation
by: Asim Joshi, et al.
Published: (2022-08-01)